Title: Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis

Authors:

Tomas Buchler (tomas.buchler@ftn.cz)
Tomas Pavlik (pavlik@iba.muni.cz)
Bohuslav Melichar (bohuslav.melichar@fnol.cz)
Zbynek Bortlicek (bortlicek@iba.muni.cz)
Zuzana Usiakova (zuzkausiak@seznam.cz)
Ladislav Dusek (dusek@iba.muni.cz)
Igor Kiss (kiss@mou.cz)
Milan Kohoutek (kohoutek@bnzlin.cz)
Vera Benesova (benesovav@nemji.cz)
Rostislav Vyzula (vyzula@mou.cz)
Jitka Abrahamova (jitka.abrahamova@ftn.cz)
Radka Obermannova (obermannova@mou.cz)

Version: 2 Date: 24 April 2013

Author’s response to reviews:

Covering letter - Query
MS: 4787665897523729

24 APR 2013

Dear Editor,

thank you for your query regarding the ethical compliance statement.

The following section has been added to the manuscript:
The study has been carried out in compliance with the Helsinki declaration and the registry has been approved by institutional ethical committees of the participating comprehensive cancer centres (the list of the 20 centres can be found at http://corect.registry.cz/index-en.php?pg=participating-centres).

Yours sincerely

Dr Tomas Buchler
Corresponding Author